Entry Point Capital, LLC C4 Therapeutics, Inc. Transaction History
Entry Point Capital, LLC
- $171 Million
- Q3 2024
Shares
2 transactions
Others Institutions Holding CCCC
# of Institutions
130Shares Held
63.5MCall Options Held
670KPut Options Held
54.8K-
Lynx1 Capital Management LP San Juan, PR6.88MShares$30.1 Million14.04% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT6.6MShares$28.9 Million3.2% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT5.68MShares$24.9 Million0.16% of portfolio
-
Ra Capital Management, L.P. Boston, MA4.88MShares$21.4 Million0.39% of portfolio
-
Black Rock Inc. New York, NY4.55MShares$19.9 Million0.0% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $214M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...